Samuel Klempner, MD

Samuel Klempner, MD
 

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA

In what types of solid tumors has mutation-directed therapy been shown to improve patient outcomes, including progression-free survival and overall (OS)? Video

In what types of solid tumors has mutation-directed therapy been shown to improve patient outcomes, including progression-free survival and overall (OS)?

In what types of solid tumors has mutation-directed therapy been shown to improve patient outcomes, including progression-free survival and overall (OS)?
Samuel Klempner, MD

Samuel Klempner, MD

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes? Video

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...
Samuel Klempner, MD

Samuel Klempner, MD

How does NGS vs. "Hot Spot" testing address the changes in cancer treatment, toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types? Video

How does NGS vs. "Hot Spot" testing address the changes in cancer treatment, toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types?

How does NGS vs. “Hot Spot” testing address the fundamental changes that systemic cancer treatment is undergoing, e.g. moving away from a paradigm in which histopathologically-defined disease is treated primarily with cytotoxic chemotherapy, ...
Samuel Klempner, MD

Samuel Klempner, MD

What have we learned about resistance to molecular targets, and how have serial NGS assessments with progressive biopsies helped us understand drug resistance and sequential therapies? Video

What have we learned about resistance to molecular targets, and how have serial NGS assessments with progressive biopsies helped us understand drug resistance and sequential therapies?

What have we learned about resistance to molecular targets, for example, in the area of ALK mutations, and how have serial NGS assessments with progressive biopsies helped our understanding of drug resistance and sequential lines of therapies ...
Samuel Klempner, MD

Samuel Klempner, MD

What guidance can you give when the F1M CGP profile reveals multiple relevant, actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist? Video

What guidance can you give when the F1M CGP profile reveals multiple relevant, actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist?

What guidance can you give in those cases in which the F1M CGP profile reveals multiple relevant, actionable mutations? On what basis would you select targeted therapies when multiple significant genomic alterations or rearrangements co-exist?
Samuel Klempner, MD

Samuel Klempner, MD

Does FoundationOne's comprehensive NGS genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Video

Does FoundationOne's comprehensive NGS genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal?

Does FoundationOne’s comprehensive NGS genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically ...
Samuel Klempner, MD

Samuel Klempner, MD

What is the optimal timing and sequence for incorporating NGS CGP in cancer patients? Are there guidelines or established protocols for a genomically-informed approach you can provide? Video

What is the optimal timing and sequence for incorporating NGS CGP in cancer patients? Are there guidelines or established protocols for a genomically-informed approach you can provide?

What is the optimal timing and sequence for incorporating NGS CGP in cancer patients? At the time of presentation? After failure of neoadjuvant cytotoxic therapy? Are there guidelines or established protocols for a genomically-informed ...
Samuel Klempner, MD

Samuel Klempner, MD

What do the evolutionary studies of tumor progression--and heterogeneity--teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in metastatic cancer? Video

What do the evolutionary studies of tumor progression--and heterogeneity--teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in metastatic cancer?

What do the evolutionary studies of tumor progression—and heterogeneity—teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in patients with metastatic cancer?
Samuel Klempner, MD

Samuel Klempner, MD

Which of the four classes of genomic alterations--base substitutions, insertions and deletions, copy number alterations, and rearrangements--can a typical multi-gene "Hot Spot" test detect? Video

Which of the four classes of genomic alterations--base substitutions, insertions and deletions, copy number alterations, and rearrangements--can a typical multi-gene "Hot Spot" test detect?

Which of the four classes of genomic alterations—base substitutions, insertions and deletions, copy number alterations, and rearrangements can a typical multi-gene “Hot Spot” test detect? Which alterations does it fail to detect and why is NGS preferable?
Samuel Klempner, MD

Samuel Klempner, MD

Why are current genomic testing models based on targeted sequencing ("Hot Spot") unsustainable given what we know about genomically-targeted therapy? Video

Why are current genomic testing models based on targeted sequencing ("Hot Spot") unsustainable given what we know about genomically-targeted therapy?

Why are current genomic testing models based on targeted sequencing (“Hot Spot”) unsustainable given what we know about genomically-targeted therapy; and why have comprehensive genomic profiling (CGP) NGS platforms, such as those developed ...
Samuel Klempner, MD

Samuel Klempner, MD

What is the current and emerging role of liquid biopsies? Video

What is the current and emerging role of liquid biopsies?

What is the current and emerging role of liquid biopsies?
Samuel Klempner, MD

Samuel Klempner, MD